Abstract:OBJECTIVES:The incidence of prostate cancer is increasing every year, and precision diagnosis and treatment can help reduce unnecessary prostate punctures for prostate cancer patients in the gray area. This study aims to investigate the diagnostic value of 18F-prostate specific membrane antigen (PSMA) imaging combined with prostate specific antigen (PSA)-derived indicators for gray zone prostate cancer. METHODS:A total of 107 patients who underwent 18F-PSMA PET/CT imaging for suspicious prostate cancer with tPSA of 4 to 10 μg/L (PSA gray zone) in a hospital were retrospectively included, and were divided into a prostate cancer group and a non-prostate cancer group based on pathological findings. Patients underwent PSA testing, 18F-PSMA, and abdominal ultrasound, and age, tPSA, fPSA, f/tPSA, prostate volume, PSA density (PSAD), maximum standardized uptake value (SUVmax), and molecular imaging prostate specific membrane antigen (miPSMA) score were compared between the 2 groups. Multivariate logistic regression was used to analyze the influencing factors the diagnosis of gray zone prostate cancer. Receiver operating characteristic (ROC) curves were constructed to evaluate the efficacy of PSAD and SUVmax alone and in combination in diagnosing gray zone prostate cancer. RESULTS:The volume of the prostate cancer group [42.00(34.00, 58.00) cm3 vs 49.00(41.27, 60.41) cm3] was smaller than that of the non-prostate cancer group (Z=-2.376, P=0.017), and the PSAD [(0.18±0.06) μg/(L·cm3) vs 0.15±0.05 μg/(L·cm3)] and SUVmax [18.63(8.03, 28.57) vs 9.33(5.90, 13.52)] were higher than those in the non-prostate cancer group (both P<0.05). The percentage of miPSMA score ≥2 in the prostate cancer group was higher than that in the non-prostate cancer group (χ2=40.987, P<0.001). PSAD (OR=22.154, 95% CI 1.430 to 873.751, P=0.042) and SUVmax (OR=1.301, 95% CI 1.034 to 1.678, P=0.009) were independent influential factors for the diagnosis of prostate cancer in the gray zone. The optimal cut-off values of PSAD and SUVmax were 0.22 μg/(L·cm3) and 8.02, respectively, and the AUCs for the diagnosis of prostate cancer in the gray zone alone and in combination were 0.628 (95% CI 0.530 to 0.720, P<0.05) and 0.806 (95% CI 0.718 to 0.876, P<0.05), 0.847 (95% CI 0.765 to 0.910, P<0.05), with sensitivities of 41.03%, 76.92%, and 74.36% and specificities of 79.41%, 89.71%, and 92.65%, respectively. CONCLUSIONS:PSAD and SUVmax are increased in patients with gray zone prostate cancer, and the combination of PSAD and SUVmax is of high value in diagnosing gray zone prostate cancer.

Clinical analysis of prostate cancer in PSA grey zone

Diagnostic value comparison of PSAM and PSAMR on PSA grey zone in prostate cancer by ROC curve analysis

Multivariate study of factors affecting the results of prostate biopsy in PSA grey zone

Improving the Detection Rate of Prostate Cancer in the Gray Zone of PI-RADS V2 and Serum Tpsa by Using Prostate-Specific Antigen–age Volume

Diagnostic value of 18F-PSMA-1007 PET/CT combined with prostate specific antigen derived indicators in gray area prostate cancer.

Do prostate-specific antigen parameters have a similar role in predicting prostate cancer regardless of serum testosterone levels in men with gray-zone prostate-specific antigen levels?

Diagnosis Significance of F/t Ratio and PSA Density for Prostate Cancer with Total PSA in Diagnostic Gray Zone

Transition Zone PSA Density Improves the Prostate Cancer Detection Rate Both in PSA 4.0-10.0 and 10.1-20.0 Ng/ml in Chinese Men

Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?

Clinical Application of Free/total PSA Ratio in the Diagnosis of Prostate Cancer in Men over 50 Years of Age with Total PSA Levels of 2.0–25.0 Ng Ml-1 in Western China

Using Clinical Parameters to Predict Prostate Cancer and Reduce the Unnecessary Biopsy among Patients with PSA in the Gray Zone

Clinicopathologic analysis of prostate biopsy in men younger than 50 years of age with prostate-specific antigen 4-10 μg/L

Value of F/tpsad and PSAD in PSA Gray Zone in the Diagnosis of Benign Prostatic Hyperplasia and Prostatic Cancer

A multicenter retrospective study on evaluation of predicative factors for positive biopsy of prostate cancer in real-world setting

Study On The Diagnostic Value Of Various Volume-Adjusted Psa Derivatives In Prostate Cancer In South Chinese Populations

Clinical Features of High-Risk Prostate Cancer with Low Serum Levels of Prostate Specific Antigen

The Comparative Study on the Application Value of Transperineal Prostate Combined Biopsy and Transrectal Prostate Systematic Biopsy in Diagnosing Prostate Cancer in Patients with Different PSA Zones.

Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels

Clinical Analysis of Prostate Cancer in Young Men under 50 Years

Age of prostate specific antigen 4 ～ 10 mu g/L patient's cancer detection and research on the effects of illness

Clinical and pathological analysis of prostate cancer with low level of serum prostate specific antigen: a report of 4 elderly cases and literatures review